Literature DB >> 16973558

Delayed biosynthesis of varicella-zoster virus glycoprotein C: upregulation by hexamethylene bisacetamide and retinoic acid treatment of infected cells.

Johnathan Storlie1, Wallen Jackson, Jennifer Hutchinson, Charles Grose.   

Abstract

In the course of examining the trafficking pathways of varicella-zoster virus (VZV) glycoproteins gE, gI, gH, and gB, we discovered that all four are synthesized within 4 to 6 h postinfection (hpi) in cultured cells. Thereafter, they travel via the trans-Golgi network to the outer cell membrane. When we carried out a similar analysis on VZV gC, we observed little gC biosynthesis in the first 72 hpi. Further examination disclosed that gC was present in the inocula of infected cells, but no new gC biosynthesis occurred during the first 24 to 48 h thereafter, during which time new synthesis of gE, gH, and major capsid protein was easily detectable. Similarly, delayed gC biosynthesis was confirmed with three different VZV strains and two different cell lines. Bioinformatics analyses disclosed the presence of PBX/HOX consensus binding domains in the promoter/enhancer regions of the genes for VZV gC and ORF4 protein (whose orthologs transactivate gC in other herpesviruses). Bioinformatics analysis also identified two HOXA9 activation regions on ORF4 protein. Treatment of infected cultures with chemicals known to induce the production of PBX/HOX transcription proteins, namely, hexamethylene bisacetamide (HMBA) and retinoic acid, led to more rapid gC biosynthesis. Immunoblotting demonstrated a fivefold increase in the HOXA9 protein after HMBA treatment. In summary, these results documented that gC was not produced during early VZV replication cycles, presumably related to a deficiency in the PBX/HOX transcription factors. Furthermore, these results explain the apparent spontaneous loss of VZV gC in some passaged viruses, as well as other anomalous gC results.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16973558      PMCID: PMC1617256          DOI: 10.1128/JVI.00668-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  HOXA9 forms triple complexes with PBX2 and MEIS1 in myeloid cells.

Authors:  W F Shen; S Rozenfeld; A Kwong; L G Köm ves; H J Lawrence; C Largman
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

2.  Global analysis of herpes simplex virus type 1 transcription using an oligonucleotide-based DNA microarray.

Authors:  S W Stingley; J J Ramirez; S A Aguilar; K Simmen; R M Sandri-Goldin; P Ghazal; E K Wagner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  MatInspector and beyond: promoter analysis based on transcription factor binding sites.

Authors:  K Cartharius; K Frech; K Grote; B Klocke; M Haltmeier; A Klingenhoff; M Frisch; M Bayerlein; T Werner
Journal:  Bioinformatics       Date:  2005-04-28       Impact factor: 6.937

4.  UL54-null pseudorabies virus is attenuated in mice but productively infects cells in culture.

Authors:  Jennifer A Schwartz; Elizabeth E Brittle; Ashley E Reynolds; Lynn W Enquist; Saul J Silverstein
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

5.  Recent steroid therapy increases severity of varicella infections in children with acute lymphoblastic leukemia.

Authors:  Garick Hill; Allen R Chauvenet; James Lovato; Thomas W McLean
Journal:  Pediatrics       Date:  2005-10       Impact factor: 7.124

6.  Cytodifferentiating agents affect the replication of herpes simplex virus type 1 in the absence of functional VP16.

Authors:  C M Preston; M McFarlane
Journal:  Virology       Date:  1998-09-30       Impact factor: 3.616

7.  Visceral varicella-zoster after bone marrow transplantation: report of a case series and review of the literature.

Authors:  D S David; B R Tegtmeier; M R O'Donnell; I B Paz; T M McCarty
Journal:  Am J Gastroenterol       Date:  1998-05       Impact factor: 10.864

8.  Aberrant intracellular localization of Varicella-Zoster virus regulatory proteins during latency.

Authors:  O Lungu; C A Panagiotidis; P W Annunziato; A A Gershon; S J Silverstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

9.  Antigenic variation of varicella zoster virus Fc receptor gE: loss of a major B cell epitope in the ectodomain.

Authors:  R A Santos; J A Padilla; C Hatfield; C Grose
Journal:  Virology       Date:  1998-09-15       Impact factor: 3.616

10.  Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse.

Authors:  J F Moffat; L Zerboni; P R Kinchington; C Grose; H Kaneshima; A M Arvin
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

View more
  17 in total

1.  Aberrant virion assembly and limited glycoprotein C production in varicella-zoster virus-infected neurons.

Authors:  Charles Grose; Xiaoli Yu; Randall J Cohrs; John E Carpenter; Jacqueline L Bowlin; Don Gilden
Journal:  J Virol       Date:  2013-06-26       Impact factor: 5.103

2.  Dysregulated Glycoprotein B-Mediated Cell-Cell Fusion Disrupts Varicella-Zoster Virus and Host Gene Transcription during Infection.

Authors:  Stefan L Oliver; Edward Yang; Ann M Arvin
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

3.  Varicella-Zoster Virus Glycoproteins: Entry, Replication, and Pathogenesis.

Authors:  Stefan L Oliver; Edward Yang; Ann M Arvin
Journal:  Curr Clin Microbiol Rep       Date:  2016-09-09

4.  Recombinant simian varicella viruses induce immune responses to simian immunodeficiency virus (SIV) antigens in immunized vervet monkeys.

Authors:  Yang Ou; Vicki Traina-Dorge; Kara A Davis; Wayne L Gray
Journal:  Virology       Date:  2007-04-16       Impact factor: 3.616

5.  Role of the IE62 consensus binding site in transactivation by the varicella-zoster virus IE62 protein.

Authors:  Kris White; Hua Peng; John Hay; William T Ruyechan
Journal:  J Virol       Date:  2010-02-03       Impact factor: 5.103

6.  Discordant varicella-zoster virus glycoprotein C expression and localization between cultured cells and human skin vesicles.

Authors:  Johnathan Storlie; John E Carpenter; Wallen Jackson; Charles Grose
Journal:  Virology       Date:  2008-10-26       Impact factor: 3.616

7.  Varicella-zoster virus infection induces autophagy in both cultured cells and human skin vesicles.

Authors:  Marie-Noëlle Takahashi; Wallen Jackson; Donna T Laird; Timothy D Culp; Charles Grose; John I Haynes; Luca Benetti
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

8.  COMMENTARY: Significantly less anti-gC antibody detectable in sera collected after varicella vaccination than after the disease varicella.

Authors:  Charles Grose; Young Juhn
Journal:  Pediatr Infect Dis J       Date:  2012-11       Impact factor: 2.129

9.  The attenuated genotype of varicella-zoster virus includes an ORF0 transitional stop codon mutation.

Authors:  Geoffrey A Peters; Shaun D Tyler; John E Carpenter; Wallen Jackson; Yasuko Mori; Ann M Arvin; Charles Grose
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

10.  RNA-seq analysis of host and viral gene expression highlights interaction between varicella zoster virus and keratinocyte differentiation.

Authors:  Meleri Jones; Inga R Dry; Dan Frampton; Manuraj Singh; Ravinder K Kanda; Michael B Yee; Paul Kellam; Michael Hollinshead; Paul R Kinchington; Edel A O'Toole; Judith Breuer
Journal:  PLoS Pathog       Date:  2014-01-30       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.